Seeman P
Department of Pharmacology, University of Toronto, Canada.
Neuropsychopharmacology. 1992 Dec;7(4):261-84.
Dopamine (DA) D2, D3, and D4 receptors are targets for antipsychotic drugs. The recent cloning, deoxyribonucleic acid sequencing, and brain location of these receptors provide new insight on the DA hypothesis of schizophrenia, particularly for the basis of antipsychotic therapy of schizophrenia. In schizophrenia brain tissue, D2 receptors are elevated and have lost the link to D1 receptors. Brain positron-emission tomography studies of patients may also reveal elevated D2, depending on the method used. Hallucinations and positive symptoms are blocked when about 70% of the D2 receptors are occupied by neuroleptic drugs. An analysis of the literature indicates that therapeutic concentrations of antipsychotic drugs (in the patient's cerebrospinal fluid or plasma water) act primarily at D2 receptors, with the exception of clozapine, which acts at D4 receptors.
多巴胺(DA)D2、D3和D4受体是抗精神病药物的作用靶点。这些受体最近的克隆、脱氧核糖核酸测序及脑内定位为精神分裂症的多巴胺假说提供了新的见解,尤其是对于精神分裂症抗精神病治疗的基础。在精神分裂症脑组织中,D2受体升高且与D1受体失去联系。根据所采用的方法,对患者进行的脑正电子发射断层扫描研究也可能显示D2受体升高。当约70%的D2受体被抗精神病药物占据时,幻觉和阳性症状会被阻断。文献分析表明,抗精神病药物的治疗浓度(在患者脑脊液或血浆水中)主要作用于D2受体,但氯氮平除外,它作用于D4受体。